187 related articles for article (PubMed ID: 28687498)
1. Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy.
Jiang Y; Liu W; Li T; Hu Y; Chen S; Xi S; Wen Y; Huang L; Zhao L; Xiao C; Huang X; Han Z; Liu H; Qi X; Yang Y; Yu J; Cai S; Li G
EBioMedicine; 2017 Aug; 22():78-88. PubMed ID: 28687498
[TBL] [Abstract][Full Text] [Related]
2. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.
Jiang Y; Xie J; Han Z; Liu W; Xi S; Huang L; Huang W; Lin T; Zhao L; Hu Y; Yu J; Zhang Q; Li T; Cai S; Li G
Clin Cancer Res; 2018 Nov; 24(22):5574-5584. PubMed ID: 30042208
[No Abstract] [Full Text] [Related]
3. PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy.
Sobhani N; Generali D; Roviello G
EBioMedicine; 2017 Aug; 22():18-19. PubMed ID: 28688823
[No Abstract] [Full Text] [Related]
4. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Jeong SH; Han JH; Kim JH; Ahn MS; Hwang YH; Lee HW; Kang SY; Park JS; Choi JH; Lee KJ; Sheen SS; Lim HY
Dig Dis Sci; 2011 Jan; 56(1):131-8. PubMed ID: 20503071
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
[TBL] [Abstract][Full Text] [Related]
6. PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy.
Chen J; Lu H; Yan D; Cui F; Wang X; Yu F; Xue Y; Feng X; Wang J; Wang X; Jiang T; Zhang M; Zhao S; Yu Y; Tang H; Peng Z
Oncotarget; 2015 Jan; 6(1):355-67. PubMed ID: 25426562
[TBL] [Abstract][Full Text] [Related]
7. PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer.
Huang W; Han Z; Sun Z; Feng H; Zhao L; Yuan Q; Chen C; Yu S; Hu Y; Yu J; Liu H; Li G; Jiang Y
Cell Death Dis; 2022 Jul; 13(7):658. PubMed ID: 35902562
[TBL] [Abstract][Full Text] [Related]
8. Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Domagala W
Cell Oncol (Dordr); 2014 Feb; 37(1):17-28. PubMed ID: 24277474
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Kim KH; Kwon HC; Oh SY; Kim SH; Lee S; Kwon KA; Jang JS; Kim MC; Kim SJ; Kim HJ
Biomarkers; 2011 Feb; 16(1):74-82. PubMed ID: 21133646
[TBL] [Abstract][Full Text] [Related]
12. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study.
Badary DM; Elkabsh MM; Mady HH; Gabr A; Kroosh SS
Appl Immunohistochem Mol Morphol; 2020; 28(10):741-747. PubMed ID: 32118594
[TBL] [Abstract][Full Text] [Related]
14. Effect of 5-fluorouracil on excision repair cross-complementing 1 expression and consequent cytotoxicity regulation in human gastric cancer cells.
Liu JL; Huang WS; Lee KC; Tung SY; Chen CN; Chang SF
J Cell Biochem; 2018 Nov; 119(10):8472-8480. PubMed ID: 30011079
[TBL] [Abstract][Full Text] [Related]
15. A 21‑gene Support Vector Machine classifier and a 10‑gene risk score system constructed for patients with gastric cancer.
Jiang H; Gu J; Du J; Qi X; Qian C; Fei B
Mol Med Rep; 2020 Jan; 21(1):347-359. PubMed ID: 31939629
[TBL] [Abstract][Full Text] [Related]
16. Tumor Immune Microenvironment and Chemosensitivity Signature for Predicting Response to Chemotherapy in Gastric Cancer.
Jiang Y; Xie J; Huang W; Chen H; Xi S; Han Z; Huang L; Lin T; Zhao LY; Hu YF; Yu J; Cai SR; Li T; Li G
Cancer Immunol Res; 2019 Dec; 7(12):2065-2073. PubMed ID: 31615816
[TBL] [Abstract][Full Text] [Related]
17. Expression of p21WAF1 in Astler-Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy.
Sulzyc-Bielicka V; Domagala P; Urasinska E; Bielicki D; Safranow K; Domagala W
Virchows Arch; 2011 Apr; 458(4):431-8. PubMed ID: 21369800
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
